ERBB2 and gastric cancer: Similarly, in HER2-amplified gastric cancer cells that became resistant to afatinib, a TKI targeting the ErbB family of receptors, as a result of MET amplification, dual inhibition of HER2 and MET effectively suppressed tumor growth [166].